NCT06229041View on ClinicalTrials.gov

Total Neoadjuvant Treatment ±Immunotherapy for High Risk Locally Advanced Rectal Cancer (TNTi)

PHASE3RecruitingINTERVENTIONAL
Enrollment

472

Participants

Timeline

Start Date

March 29, 2023

Primary Completion Date

October 1, 2027

Study Completion Date

October 1, 2029

Conditions
Rectal Cancer
Interventions
DRUG

Camrelizumab ＋Immunotherapy

Camrelizumab was used in preoperative treatment.

Trial Locations (1)

100142

RECRUITING

Beijing Cancer Hospital, Beijing

All Listed Sponsors
collaborator

Beijing Nanjiao Cancer Hospital

UNKNOWN

lead

Peking University Cancer Hospital & Institute

OTHER